Wednesday, June 10, 2026
🇺🇸 FDA

Intelligence · Patents

Patents expiring in 2032

Annual patent cliff calendar for 2032 — US pharmaceutical patents by expiration date.

Patents
1,150

Quick answer

1,150 indexed pharmaceutical patents have expiration dates in 2032. Browse by soonest expiry with links to assignee companies and related drugs.

  1. US 8178076

    Diagnosis and assessment of skeletal related disease using calcium 41

    The Regents of the University of California · Granted Tue May 15 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 10 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 8178513

    Heterocyclic aspartyl protease inhibitors

    Pharmacopeia Drug Discovery, Inc. · Granted Tue May 15 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 10 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 8178537

    Solid state forms of varenicline salts and processes for preparation thereof

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue May 15 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 10 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 8178531

    Antiviral agents

    Enanta Pharmaceuticals, Inc. · Granted Tue May 15 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 10 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 8178109

    Compositions and methods of use for MGD-CSF in disease treatment

    Five Prime Therapeutics, Inc. · Granted Tue May 15 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 10 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 8178298

    Patched polypeptides and uses related thereto

    The Regents of the University of California · Granted Tue May 15 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 10 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 8178534

    cMET inhibitors

    Takeda Pharmaceutical Company Limited · Granted Tue May 15 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 10 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 8178555

    Apoptosis signal-regulating kinase 1 inhibitors

    Takeda Pharmaceutical Company Limited · Granted Tue May 15 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 10 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 8178671

    Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds

    Rigel Pharmaceuticals, Inc. · Granted Tue May 15 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 10 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 8183358

    Puumala virus full-length M segment-based DNA vaccines

    The United States of America as represented by the Secretary of the Army · Granted Tue May 22 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 17 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 8183207

    Treatment of osteolytic disorders and cancer using CSF1R extracellular domain fusion molecules

    Five Prime Therapeutics, Inc. · Granted Tue May 22 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 17 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 8183014

    High affinity antibodies to human IL-6 receptor

    REGENERON PHARMACEUTICALS, INC. · Granted Tue May 22 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 17 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 8182807

    Method for inhibiting reperfusion injury in the brain

    Board of Regents of the University of Nebraska by and behalf of the University of Nebraska Medical Center · Granted Tue May 22 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 17 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 8182801

    Method for preparing water-soluble polymer derivatives bearing a terminal carboxylic acid

    Nektar Therapeutics · Granted Tue May 22 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 17 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 8182835

    Sustained-release liposomal anesthetic compositions

    Pacira Pharmaceuticals, Inc. · Granted Tue May 22 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 17 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 8182842

    Physico-chemical-managed killing of penicillin-resistant static and growing gram-positive and gram-negative vegetative bacteria

    The United States of America as represented by the Administrator of the National Aeronautics and Space Administration · Granted Tue May 22 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 17 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 8183282

    Therapeutic uses of urolithins

    The Regents of the University of California · Granted Tue May 22 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 17 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 8182860

    Dental filler

    JGC Catalysts and Chemicals Ltd. · Granted Tue May 22 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 17 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 8183009

    Assaying cellular markers for the evaluation of tumors

    Precision Therapeutics, Inc. · Granted Tue May 22 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 17 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 8183012

    Methods and composition for the production of orthogonal tRNA-aminoacyltRNA synthetase pairs

    The Regents of the University of California · Granted Tue May 22 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 17 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 8183212

    Compound having GPR54 agonistic activity

    Takeda Pharmaceutical Company Limited · Granted Tue May 22 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 17 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 8183274

    Treatment of hyperproliferative disorders with diarylhydantoin compounds

    The Regents of the University of California · Granted Tue May 22 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 17 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 8183285

    Therapeutic agent for irritable bowel syndrome and methods thereof

    Takeda Pharmaceutical Company Limited · Granted Tue May 22 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 17 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 8183361

    Oligonucleotide-containing pharmacological compositions and their use

    Lakewood Amedex, Inc. · Granted Tue May 22 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 17 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 8183362

    Method and medicament for inhibiting the expression of a given gene

    Alnylam Pharmaceuticals, Inc. · Granted Tue May 22 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 17 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 8183338

    Sterically hindered poly(ethylene glycol) alkanoic acids and derivatives thereof

    Nektar Therapeutics · Granted Tue May 22 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 17 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 8183373

    Solid state forms of sitagliptin salts

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue May 22 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 17 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 8183204

    Methods and compositions for increasing skin remodeling

    Summit Associates International Inc. · Granted Tue May 22 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 17 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 8185186

    Systems and methods for tissue imaging

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue May 22 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 17 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 8183344

    Inactivation resistant factor VIII

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue May 22 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 17 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 8182836

    Abuse-resistant oral dosage forms and method of use thereof

    Elite Laboratories, Inc. · Granted Tue May 22 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 17 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 8188067

    Formulations of 6-mercaptopurine

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue May 29 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 24 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 8188049

    Peptides having activities of epidermal growth factor and its uses

    CAREGEN CO., LTD. · Granted Tue May 29 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 24 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 8188055

    Inactivators of O6-alkylguanine-DNA alkyltransferase

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue May 29 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 24 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 8188061

    RNAi modulation of APOB and uses thereof

    Alnylam Pharmaceuticals, Inc. · Granted Tue May 29 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 24 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 8188096

    Protein kinase targeted therapeutics

    Northwestern University · Granted Tue May 29 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 24 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 8188132

    Linked dibenzimidazole derivatives

    Enanta Pharmaceuticals, Inc. · Granted Tue May 29 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 24 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 8188149

    Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue May 29 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 24 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 8188214

    Brachyury polypeptides and methods for use

    The United States of America as Represented by the Secretary of the Department of Health and Human Services · Granted Tue May 29 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 24 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 8188072

    Benzodiazepinone compounds useful in the treatment of skin conditions

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue May 29 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 24 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 8188221

    Peptide homing to brain tumors

    The Regents of the University of California, UCSF · Granted Tue May 29 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 24 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 8188095

    Gyrase inhibitors and uses thereof

    Vertex Pharmaceuticals Incorporated · Granted Tue May 29 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 24 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 8188219

    Bone morphogenic protein binding peptide

    The Regents of the University of California · Granted Tue May 29 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 24 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 8188276

    2,4-pyrimidinediamine compounds and their uses

    Rigel Pharmaceuticals, Inc. · Granted Tue May 29 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 24 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 8188259

    Oligonucleotide-containing pharmacological compositions and their use

    Lakewood Amedex, Inc. · Granted Tue May 29 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 24 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 8188294

    Process for preparing biphenyl imidazole compounds

    Theravance, Inc. · Granted Tue May 29 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 24 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 8188283

    Modulators of cystic fibrosis transmembrane conductance regulator

    Vertex Pharmaceuticals Incorporated · Granted Tue May 29 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 24 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 8188289

    Conformationally restricted urea inhibitors of soluble epoxide hydrolase

    The Regents of the University of California · Granted Tue May 29 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 24 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many pharma patents expire in 2032?

1,150 published patents in our USPTO index have expiration dates falling in calendar year 2032.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.